Neurocrine Biosciences (NASDAQ:NBIX) Earns “Buy” Rating from Needham & Company LLC

Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “buy” rating reaffirmed by equities researchers at Needham & Company LLC in a research report issued on Monday,Benzinga reports. They presently have a $185.00 price target on the stock. Needham & Company LLC’s price objective suggests a potential upside of 39.33% from the company’s current price.

Several other analysts have also weighed in on NBIX. Citigroup boosted their price objective on Neurocrine Biosciences from $203.00 to $204.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Mizuho lifted their target price on Neurocrine Biosciences from $146.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, December 12th. Wolfe Research began coverage on Neurocrine Biosciences in a report on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 price target for the company. Wells Fargo & Company dropped their price target on Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Finally, Zacks Research cut Neurocrine Biosciences from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $175.10.

Neurocrine Biosciences Trading Up 0.9%

NASDAQ NBIX traded up $1.18 during trading hours on Monday, reaching $132.78. 884,121 shares of the company traded hands, compared to its average volume of 1,129,526. The stock has a market capitalization of $13.33 billion, a PE ratio of 28.60, a PEG ratio of 0.69 and a beta of 0.35. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $160.18. The company has a 50 day moving average of $131.56 and a two-hundred day moving average of $139.10.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing the consensus estimate of $2.36 by ($0.48). The company had revenue of $805.50 million during the quarter, compared to the consensus estimate of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.Neurocrine Biosciences’s revenue for the quarter was up 28.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.69 EPS. On average, equities research analysts anticipate that Neurocrine Biosciences will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of the business’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at $18,632,008.90. The trade was a 20.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently made changes to their positions in the business. AlTi Global Inc. boosted its position in shares of Neurocrine Biosciences by 1.0% during the third quarter. AlTi Global Inc. now owns 6,828 shares of the company’s stock worth $959,000 after buying an additional 70 shares during the period. Huntington National Bank increased its position in Neurocrine Biosciences by 12.6% in the 4th quarter. Huntington National Bank now owns 678 shares of the company’s stock valued at $96,000 after acquiring an additional 76 shares during the period. Vanguard Personalized Indexing Management LLC raised its stake in Neurocrine Biosciences by 0.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock valued at $1,560,000 after acquiring an additional 77 shares in the last quarter. Perigon Wealth Management LLC raised its stake in Neurocrine Biosciences by 3.1% during the 4th quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock valued at $367,000 after acquiring an additional 78 shares in the last quarter. Finally, Motley Fool Asset Management LLC boosted its position in Neurocrine Biosciences by 4.8% during the 4th quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock worth $240,000 after acquiring an additional 78 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition adds VYKAT™ XR (diazoxide choline), a first‑and‑only FDA‑approved therapy for hyperphagia in Prader‑Willi Syndrome, plus intellectual property extending into the mid‑2040s — expands Neurocrine’s commercial portfolio to three first‑in‑class medicines and supports long‑term revenue growth. Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster
• Positive Sentiment: Company frames the deal as strategic expansion into endocrinology/rare disease, aiming to create a more diversified, durable revenue platform beyond neuroscience. Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
• Neutral Sentiment: Deal terms: all‑cash $53.00 per share, ~ $2.9B equity value — represents ~34% premium to SLNO close on April 2 and ~51% above its 30‑day average; conference call and M&A transcript provide further deal context for investors. Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript
• Neutral Sentiment: Soleno shares jumped sharply on the bid (reports show 28–40% premarket gains), reflecting the deal’s immediate value transfer to SLNO shareholders while highlighting the market’s appetite for obesity/endocrine assets. Soleno shares jump 33% as Neurocrine expands into metabolic diseases with $2.9 billion buyout
• Negative Sentiment: Neurocrine’s shares fell after the announcement — investors are concerned about the cash outlay and whether the $53 price is expensive given execution risk in orphan/metabolic markets. This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.
• Negative Sentiment: Analysts flag balanced risk/reward: BMO kept a Hold and $140 PT, citing favorable acquisition prospects offset by long‑term Ingrezza and orphan‑market execution risks — implies limited near‑term analyst upside. Balanced View on Neurocrine Biosciences: Favorable Soleno Acquisition Prospects Offset by Long-Term Ingrezza and Orphan Market Execution Risks

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.